Drugs /

azd8186

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.

Clinical Trials

View Clinical Trials for azd8186

Azd8186 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating azd8186, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

PIK3CB Mutation, PTEN Loss, and ER Negative are the most frequent biomarker inclusion criteria for azd8186 clinical trials.

Malignant solid tumor, breast carcinoma, and gastric carcinoma are the most common diseases being investigated in azd8186 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Azd8186
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Azd8186
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating azd8186 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
azd-8186, pi3kbeta inhibitor azd8186, 1296270-45-5
Drug Categories [2]:
PI3K inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
PIK3CB, PIK3CD
NCIT ID [1]:
C107684

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.